The Experts below are selected from a list of 189 Experts worldwide ranked by ideXlab platform
Herbert Y Meltzer - One of the best experts on this subject based on the ideXlab platform.
-
changes in weight and body mass index during treatment with Melperone clozapine and typical neuroleptics
Psychiatry Research-neuroimaging, 2010Co-Authors: William V Bobo, Karuna Jayathilake, Herbert Y MeltzerAbstract:Abstract Melperone is an atypical antipsychotic drug that has been reported to be effective in treatment-resistant schizophrenia and L -DOPA psychosis. There are limited data concerning its effect on weight or body mass index (BMI). Weight and BMI were retrospectively compared in patients with schizophrenia treated with Melperone (n = 34), clozapine (n = 225), or typical neuroleptics (n = 74) for up to 3 months. Clozapine resulted in significant increases in weight and BMI from baseline to 6 weeks and 3 months. Neither Melperone nor typical neuroleptics resulted in significant weight gain at either time point. Melperone did not result in significant increases in BMI. Weight and BMI were significantly lower with Melperone compared with clozapine, but similar to typical neuroleptics. The proportion of Melperone patients who experienced a ≥ 7% weight increase was lower than that in patients treated with clozapine and similar to that in patients treated with typical neuroleptics. Percent change in weight and BMI predicted improvement in BPRS total scores at 3 months in the clozapine group, but not in the Melperone or typical neuroleptic groups. Because of the relationship between BMI and cardiovascular risk, Melperone deserves further study as both a first line treatment and as an alternative to clozapine in refractory schizophrenia.
-
Melperone an aytpical antipsychotic drug with clozapine like effect on plasma prolactin contrast with typical neuroleptics
Human Psychopharmacology-clinical and Experimental, 2009Co-Authors: William V Bobo, Karuna Jayathilake, Herbert Y MeltzerAbstract:Objective To evaluate the effect of Melperone, a butyrophenone with atypical antipsychotic properties, on plasma prolactin (PRL) concentrations compared with clozapine and typical neuroleptics. Methods Analysis of pre- and post-treatment PRL levels collected prospectively per protocol in a non-randomized study of 26 Melperone-, 76 clozapine-, and 66 neuroleptic-treated patients with schizophrenia or schizoaffective disorder. Cross-sectional analysis of a larger sample of patients with PRL data was also performed. Results For males, post-treatment PRL levels were significantly higher in the typical neuroleptic group compared with the Melperone (p = 0.0001) and clozapine (p = 0.0001) groups, with no significant difference between clozapine and Melperone. For females, post-treatment PRL levels were significantly higher in the Melperone group as compared to the clozapine group (p = 0.004). There were too few typical neuroleptic-treated females to permit analysis of this sample. However, the cross-sectional analysis of PRL data confirmed the results for Melperone- and clozapine-treated females, and showed higher PRL levels in typical neuroleptic-treated females as compared with those who received Melperone and clozapine. Conclusion Melperone did not significantly increase PRL levels in male patients. However, Melperone and typical neuroleptics caused increase in PRL levels in females. Further study of Melperone's effects on PRL concentration is warranted. Copyright © 2009 John Wiley & Sons, Ltd.
-
a comparison of two doses of Melperone an atypical antipsychotic drug in the treatment of schizophrenia
Schizophrenia Research, 2003Co-Authors: Tomiki Sumiyoshi, Karu Jayathilake, Herbert Y MeltzerAbstract:Melperone at a dose of 300 mg/day has been reported to be as effective as thiothixene and superior to placebo in the treatment of schizophrenia. Limited ability to cause extrapyramidal side effects (EPS) and absence of an effect on plasma prolactin (pPRL) levels suggests that it is an atypical antipsychotic drug. The goal of this pilot study was to determine: (1) the ability of Melperone 400 mg/day to produce greater improvement in psychopathology than Melperone 100 mg/day; and (2) to compare side effects of these two doses of Melperone. Melperone, 100 or 400 mg/day, was administered to 34 acutely hospitalized patients with schizophrenia for 6 weeks in a randomized, double-blind manner. Psychopathology, EPS, pPRL levels, and body mass index (BMI) were evaluated at baseline and 6 weeks. Twenty-seven completed the 6-week treatment. A last carried forward analysis revealed no significant difference in the ability of the two doses of Melperone to improve psychopathology as measured by the Brief Psychiatric Rating Scale (BPRS)-Total and Positive subscale, the Scale for the Assessment of Negative Symptoms (SANS), the Schedule for Affective Disorders and Schizophrenia-Disorganization subscale, and the Global Assessment Scale (GAS). Treatment with Melperone was not associated with exacerbation of EPS, or an increase in pPRL levels or BMI. The Abnormal Involuntary Movement Scale (AIMS) was not significantly changed by treatment with Melperone. These results suggest that Melperone was equally effective at doses 100 and 400 mg/day, for ameliorating psychopathology and improving overall psychiatric status in patients with schizophrenia. However, the lack of difference and a placebo control group, as well as modest degrees of change in psychopathology, require caution about assuming efficacy of either dose. The lack of significant side effects such as exacerbation of EPS, pPRL elevation, and weight gain indicates Melperone is well tolerated.
-
the effect of Melperone an atypical antipsychotic drug on cognitive function in schizophrenia
Schizophrenia Research, 2003Co-Authors: Tomiki Sumiyoshi, Karu Jayathilake, Herbert Y MeltzerAbstract:Melperone, a butyrophenone, has been shown to possess atypical antipsychotic properties, i.e. ability to produce an antipsychotic effect in man at doses that cause minimal extrapyramidal side effects. In addition, Melperone shares the following with other atypical antipsychotic drugs: (1) effectiveness for ameliorating negative symptoms; (2) no prolactin elevation; and (3) effectiveness in the treatment of some patients with neuroleptic-resistant schizophrenia. Other atypical antipsychotic drugs have been reported to improve cognitive function. This study was performed to investigate the effect of Melperone on cognitive function. Nineteen patients with schizophrenia or schizoaffective disorder, including 11 neuroleptic-resistant patients, were treated with Melperone for 6 weeks. A comprehensive neurocognitive test battery and psychopathological ratings (Brief Psychiatric Rating Scale, BPRS) were administered at baseline and after 6 weeks of Melperone treatment. Treatment with Melperone was associated with improvement in executive function, as measured by the Wisconsin Card Sorting Test (WCST)-Categories and WCST-Percent Perseveration. On the other hand, visuospatial manipulation, as measured by the Wechsler Intelligent Scale for Children-Revised (WISC-R) Maze, worsened during Melperone treatment. There were no significant changes in other domains of cognition, i.e. verbal learning and memory, verbal working memory, verbal fluency and sustained attention. Scores of WCST-Categories and Perseveration at 6 weeks were predicted from the relevant cognitive test scores at baseline and the change in BPRS Total and Positive scores. These results suggest the usefulness of Melperone for facilitating work and social function in patients with schizophrenia. The differences in the cognition-enhancing abilities between Melperone and clozapine are discussed.
-
atypical antipsychotic drugs quetiapine iloperidone and Melperone preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex role of 5 ht1a receptor agonism
Brain Research, 2002Co-Authors: Junji Ichikawa, Zhu Li, Herbert Y MeltzerAbstract:Abstract Preferential increases in both cortical dopamine (DA) and acetylcholine (ACh) release have been proposed to distinguish the atypical antipsychotic drugs (APDs) clozapine, olanzapine, risperidone and ziprasidone from typical APDs such as haloperidol. Although only clozapine and ziprasidone are directly acting 5-HT1A agonists, WAY100635, a selective 5-HT1A antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT2A and D2 blockade. However, WAY100635 does not attenuate clozapine-induced cortical ACh release. The present study determined whether quetiapine, iloperidone and Melperone, 5-HT2A/D2 antagonist atypical APDs, also increase cortical DA and ACh release, and whether these effects are related to 5-HT1A agonism. Quetiapine (30 mg/kg), iloperidone (1–10 mg/kg), and Melperone (3–10 mg/kg) increased DA and ACh release in the medial prefrontal cortex (mPFC). Iloperidone (10 mg/kg) and Melperone (10 mg/kg), but not quetiapine (30 mg/kg), produced an equivalent or a smaller increase in DA release in the nucleus accumbens (NAC), respectively, compared to the mPFC, whereas none of them increased ACh release in the NAC. WAY100635 (0.2 mg/kg), which alone did not affect DA or ACh release, partially attenuated quetiapine (30 mg/kg)-, iloperidone (10 mg/kg)- and Melperone (10 mg/kg)-induced DA release in the mPFC. WAY100635 also partially attenuated quetiapine (30 mg/kg)-induced ACh release in the mPFC, but not that induced by iloperidone (10 mg/kg) or Melperone (10 mg/kg). These results indicate that quetiapine, iloperidone and Melperone preferentially increase DA release in the mPFC, compared to the NAC via a 5-HT1A-related mechanism. However, 5-HT1A agonism may be important only for quetiapine-induced ACh release.
K Elgen - One of the best experts on this subject based on the ideXlab platform.
-
Zuclopenthixol, Melperone and haloperidol/levomepromazine in the elderly. Meta-analysis of two double-blind trials at 15 nursing homes in Norway
Current Medical Research and Opinion, 1992Co-Authors: H A Nygaard, E Fuglum, K ElgenAbstract:SummaryA meta-analysis was carried out of the data from two double-blind. multi-centre studies with identical methodology which compared the effectiveness of treatment of elderly patients with zuclopenthixol and with other antipsychotic drugs. In one study, patients were treated for 4 weeks with either zuclopenthixol or Melperone; in the other, with either zuclopenthixol or a combination of haloperidol and levomepromazine. The meta-analysis evaluated the results of 96 patients, 49 in the zuclopenthixol group and 47 in the comparison group. Doses, which were adjusted to individual patient's needs, were low as shown by the percentages of defined daily doses for each of the study drugs. The results indicated that all three treatment alternatives were effective in the treatment of elderly patients with symptoms of agitation and hostility/aggressiveness. There was a trend, however, for zuclopenthixol to have a more rapid onset of effect. Zuclopenthixol also has the advantage for both patients and nursing stuff...
-
Zuclopenthixol, Melperone and haloperidol/levomepromazine in E. Fuglum,* M.D., the elderly. Meta-analysis of two double-blind trials at 15 nursing
1992Co-Authors: H A Nygaard, K Elgen, H Lundbeck, S CopenhagenAbstract:Summary A meta-analysis was carried out of the data ,from two double-blind. multi-centre studies with identical methodology which compared the effectiveness of treatment of elderly patients with zuclopenthixol and with other antipsychotic drugs. In one study, patients were treated ,for 4 weeks with either zuclopenthixol or Melperone; in the other; with either zuclopenthixol or a combination of haloperidol and levomepromazine. The meta-analysis evaluated the results of Yh patients, 49 in the zuclopenthixol group and 47 in the comparison group. Doses, which were adjusted to individual patienth needs, were low as shown by the percentages of defined daily doses for each of the study drugs. The results indicated that all three treatment alternatives were effective in the treatment of elderly patients with symptoms of agitation and hostilitylaggressiveness. There was a trend, however; for zuclopenthixol to have a more rapid onset of’ effect. Zuclopenthixol also has the advantage for both patients and nursing stuff’ that dosage is once daily. Only few and mild side-effects were reported with the three drug regimens.
-
zuclopenthixol Melperone and haloperidol levomepromazine in the elderly meta analysis of two double blind trials at 15 nursing homes in norway
Current Medical Research and Opinion, 1992Co-Authors: H A Nygaard, E Fuglum, K ElgenAbstract:SummaryA meta-analysis was carried out of the data from two double-blind. multi-centre studies with identical methodology which compared the effectiveness of treatment of elderly patients with zuclopenthixol and with other antipsychotic drugs. In one study, patients were treated for 4 weeks with either zuclopenthixol or Melperone; in the other, with either zuclopenthixol or a combination of haloperidol and levomepromazine. The meta-analysis evaluated the results of 96 patients, 49 in the zuclopenthixol group and 47 in the comparison group. Doses, which were adjusted to individual patient's needs, were low as shown by the percentages of defined daily doses for each of the study drugs. The results indicated that all three treatment alternatives were effective in the treatment of elderly patients with symptoms of agitation and hostility/aggressiveness. There was a trend, however, for zuclopenthixol to have a more rapid onset of effect. Zuclopenthixol also has the advantage for both patients and nursing stuff...
-
zuclopenthixol Melperone and haloperidol levomepromazine in e fuglum m d the elderly meta analysis of two double blind trials at 15 nursing
1992Co-Authors: H A Nygaard, K Elgen, H Lundbeck, S CopenhagenAbstract:Summary A meta-analysis was carried out of the data ,from two double-blind. multi-centre studies with identical methodology which compared the effectiveness of treatment of elderly patients with zuclopenthixol and with other antipsychotic drugs. In one study, patients were treated ,for 4 weeks with either zuclopenthixol or Melperone; in the other; with either zuclopenthixol or a combination of haloperidol and levomepromazine. The meta-analysis evaluated the results of Yh patients, 49 in the zuclopenthixol group and 47 in the comparison group. Doses, which were adjusted to individual patienth needs, were low as shown by the percentages of defined daily doses for each of the study drugs. The results indicated that all three treatment alternatives were effective in the treatment of elderly patients with symptoms of agitation and hostilitylaggressiveness. There was a trend, however; for zuclopenthixol to have a more rapid onset of’ effect. Zuclopenthixol also has the advantage for both patients and nursing stuff’ that dosage is once daily. Only few and mild side-effects were reported with the three drug regimens.
Tomiki Sumiyoshi - One of the best experts on this subject based on the ideXlab platform.
-
a comparison of two doses of Melperone an atypical antipsychotic drug in the treatment of schizophrenia
Schizophrenia Research, 2003Co-Authors: Tomiki Sumiyoshi, Karu Jayathilake, Herbert Y MeltzerAbstract:Melperone at a dose of 300 mg/day has been reported to be as effective as thiothixene and superior to placebo in the treatment of schizophrenia. Limited ability to cause extrapyramidal side effects (EPS) and absence of an effect on plasma prolactin (pPRL) levels suggests that it is an atypical antipsychotic drug. The goal of this pilot study was to determine: (1) the ability of Melperone 400 mg/day to produce greater improvement in psychopathology than Melperone 100 mg/day; and (2) to compare side effects of these two doses of Melperone. Melperone, 100 or 400 mg/day, was administered to 34 acutely hospitalized patients with schizophrenia for 6 weeks in a randomized, double-blind manner. Psychopathology, EPS, pPRL levels, and body mass index (BMI) were evaluated at baseline and 6 weeks. Twenty-seven completed the 6-week treatment. A last carried forward analysis revealed no significant difference in the ability of the two doses of Melperone to improve psychopathology as measured by the Brief Psychiatric Rating Scale (BPRS)-Total and Positive subscale, the Scale for the Assessment of Negative Symptoms (SANS), the Schedule for Affective Disorders and Schizophrenia-Disorganization subscale, and the Global Assessment Scale (GAS). Treatment with Melperone was not associated with exacerbation of EPS, or an increase in pPRL levels or BMI. The Abnormal Involuntary Movement Scale (AIMS) was not significantly changed by treatment with Melperone. These results suggest that Melperone was equally effective at doses 100 and 400 mg/day, for ameliorating psychopathology and improving overall psychiatric status in patients with schizophrenia. However, the lack of difference and a placebo control group, as well as modest degrees of change in psychopathology, require caution about assuming efficacy of either dose. The lack of significant side effects such as exacerbation of EPS, pPRL elevation, and weight gain indicates Melperone is well tolerated.
-
the effect of Melperone an atypical antipsychotic drug on cognitive function in schizophrenia
Schizophrenia Research, 2003Co-Authors: Tomiki Sumiyoshi, Karu Jayathilake, Herbert Y MeltzerAbstract:Melperone, a butyrophenone, has been shown to possess atypical antipsychotic properties, i.e. ability to produce an antipsychotic effect in man at doses that cause minimal extrapyramidal side effects. In addition, Melperone shares the following with other atypical antipsychotic drugs: (1) effectiveness for ameliorating negative symptoms; (2) no prolactin elevation; and (3) effectiveness in the treatment of some patients with neuroleptic-resistant schizophrenia. Other atypical antipsychotic drugs have been reported to improve cognitive function. This study was performed to investigate the effect of Melperone on cognitive function. Nineteen patients with schizophrenia or schizoaffective disorder, including 11 neuroleptic-resistant patients, were treated with Melperone for 6 weeks. A comprehensive neurocognitive test battery and psychopathological ratings (Brief Psychiatric Rating Scale, BPRS) were administered at baseline and after 6 weeks of Melperone treatment. Treatment with Melperone was associated with improvement in executive function, as measured by the Wisconsin Card Sorting Test (WCST)-Categories and WCST-Percent Perseveration. On the other hand, visuospatial manipulation, as measured by the Wechsler Intelligent Scale for Children-Revised (WISC-R) Maze, worsened during Melperone treatment. There were no significant changes in other domains of cognition, i.e. verbal learning and memory, verbal working memory, verbal fluency and sustained attention. Scores of WCST-Categories and Perseveration at 6 weeks were predicted from the relevant cognitive test scores at baseline and the change in BPRS Total and Positive scores. These results suggest the usefulness of Melperone for facilitating work and social function in patients with schizophrenia. The differences in the cognition-enhancing abilities between Melperone and clozapine are discussed.
-
Melperone in the treatment of neuroleptic resistant schizophrenia
Psychiatry Research-neuroimaging, 2001Co-Authors: Herbert Y Meltzer, Tomiki Sumiyoshi, Karu JayathilakeAbstract:Abstract Melperone is an effective antipsychotic drug that has been reported to have atypical properties, i.e. low extrapyramidal side effect liability at clinically effective doses. It also does not increase serum prolactin levels. Its effectiveness for patients with neuroleptic (treatment)-resistant schizophrenia has not been evaluated. In this study, Melperone was administered, in an open trial design of 6 weeks' duration, to 44 patients with chronic neuroleptic-resistant schizophrenia. The Global Assessment Scale (GAS), Brief Psychiatric Rating Scale (BPRS) and measures of extrapyramidal symptoms and other clinical variables were assessed at baseline and 6 weeks. Thirty-seven patients completed the 6-week trial. Melperone significantly improved overall psychiatric status as measured by GAS score for all evaluable subjects [last value carried forward (LVCF) and a completers analysis]. No significant effects on BPRS measures of psychopathology scores were found in the LVCF or completers analysis. Patients who showed ≥20% decrease in the BPRS Total score ( N =7) were more likely to have high baseline psychopathology, as measured by BPRS Total and Anxiety–Depression subscales, than those who showed ≥20% increase in the BPRS Total score ( N =8). Non-responders to Melperone generally did not respond to subsequent treatment with clozapine, indicating that this group of patients was very treatment resistant. Melperone was not associated with worsening of extrapyramidal symptoms, elevation in plasma prolactin levels, or an increase in body mass index (BMI). The results suggest that a proportion of neuroleptic-resistant patients with schizophrenia respond to Melperone, which requires further controlled study.
Karu Jayathilake - One of the best experts on this subject based on the ideXlab platform.
-
a comparison of two doses of Melperone an atypical antipsychotic drug in the treatment of schizophrenia
Schizophrenia Research, 2003Co-Authors: Tomiki Sumiyoshi, Karu Jayathilake, Herbert Y MeltzerAbstract:Melperone at a dose of 300 mg/day has been reported to be as effective as thiothixene and superior to placebo in the treatment of schizophrenia. Limited ability to cause extrapyramidal side effects (EPS) and absence of an effect on plasma prolactin (pPRL) levels suggests that it is an atypical antipsychotic drug. The goal of this pilot study was to determine: (1) the ability of Melperone 400 mg/day to produce greater improvement in psychopathology than Melperone 100 mg/day; and (2) to compare side effects of these two doses of Melperone. Melperone, 100 or 400 mg/day, was administered to 34 acutely hospitalized patients with schizophrenia for 6 weeks in a randomized, double-blind manner. Psychopathology, EPS, pPRL levels, and body mass index (BMI) were evaluated at baseline and 6 weeks. Twenty-seven completed the 6-week treatment. A last carried forward analysis revealed no significant difference in the ability of the two doses of Melperone to improve psychopathology as measured by the Brief Psychiatric Rating Scale (BPRS)-Total and Positive subscale, the Scale for the Assessment of Negative Symptoms (SANS), the Schedule for Affective Disorders and Schizophrenia-Disorganization subscale, and the Global Assessment Scale (GAS). Treatment with Melperone was not associated with exacerbation of EPS, or an increase in pPRL levels or BMI. The Abnormal Involuntary Movement Scale (AIMS) was not significantly changed by treatment with Melperone. These results suggest that Melperone was equally effective at doses 100 and 400 mg/day, for ameliorating psychopathology and improving overall psychiatric status in patients with schizophrenia. However, the lack of difference and a placebo control group, as well as modest degrees of change in psychopathology, require caution about assuming efficacy of either dose. The lack of significant side effects such as exacerbation of EPS, pPRL elevation, and weight gain indicates Melperone is well tolerated.
-
the effect of Melperone an atypical antipsychotic drug on cognitive function in schizophrenia
Schizophrenia Research, 2003Co-Authors: Tomiki Sumiyoshi, Karu Jayathilake, Herbert Y MeltzerAbstract:Melperone, a butyrophenone, has been shown to possess atypical antipsychotic properties, i.e. ability to produce an antipsychotic effect in man at doses that cause minimal extrapyramidal side effects. In addition, Melperone shares the following with other atypical antipsychotic drugs: (1) effectiveness for ameliorating negative symptoms; (2) no prolactin elevation; and (3) effectiveness in the treatment of some patients with neuroleptic-resistant schizophrenia. Other atypical antipsychotic drugs have been reported to improve cognitive function. This study was performed to investigate the effect of Melperone on cognitive function. Nineteen patients with schizophrenia or schizoaffective disorder, including 11 neuroleptic-resistant patients, were treated with Melperone for 6 weeks. A comprehensive neurocognitive test battery and psychopathological ratings (Brief Psychiatric Rating Scale, BPRS) were administered at baseline and after 6 weeks of Melperone treatment. Treatment with Melperone was associated with improvement in executive function, as measured by the Wisconsin Card Sorting Test (WCST)-Categories and WCST-Percent Perseveration. On the other hand, visuospatial manipulation, as measured by the Wechsler Intelligent Scale for Children-Revised (WISC-R) Maze, worsened during Melperone treatment. There were no significant changes in other domains of cognition, i.e. verbal learning and memory, verbal working memory, verbal fluency and sustained attention. Scores of WCST-Categories and Perseveration at 6 weeks were predicted from the relevant cognitive test scores at baseline and the change in BPRS Total and Positive scores. These results suggest the usefulness of Melperone for facilitating work and social function in patients with schizophrenia. The differences in the cognition-enhancing abilities between Melperone and clozapine are discussed.
-
Melperone in the treatment of neuroleptic resistant schizophrenia
Psychiatry Research-neuroimaging, 2001Co-Authors: Herbert Y Meltzer, Tomiki Sumiyoshi, Karu JayathilakeAbstract:Abstract Melperone is an effective antipsychotic drug that has been reported to have atypical properties, i.e. low extrapyramidal side effect liability at clinically effective doses. It also does not increase serum prolactin levels. Its effectiveness for patients with neuroleptic (treatment)-resistant schizophrenia has not been evaluated. In this study, Melperone was administered, in an open trial design of 6 weeks' duration, to 44 patients with chronic neuroleptic-resistant schizophrenia. The Global Assessment Scale (GAS), Brief Psychiatric Rating Scale (BPRS) and measures of extrapyramidal symptoms and other clinical variables were assessed at baseline and 6 weeks. Thirty-seven patients completed the 6-week trial. Melperone significantly improved overall psychiatric status as measured by GAS score for all evaluable subjects [last value carried forward (LVCF) and a completers analysis]. No significant effects on BPRS measures of psychopathology scores were found in the LVCF or completers analysis. Patients who showed ≥20% decrease in the BPRS Total score ( N =7) were more likely to have high baseline psychopathology, as measured by BPRS Total and Anxiety–Depression subscales, than those who showed ≥20% increase in the BPRS Total score ( N =8). Non-responders to Melperone generally did not respond to subsequent treatment with clozapine, indicating that this group of patients was very treatment resistant. Melperone was not associated with worsening of extrapyramidal symptoms, elevation in plasma prolactin levels, or an increase in body mass index (BMI). The results suggest that a proportion of neuroleptic-resistant patients with schizophrenia respond to Melperone, which requires further controlled study.
H A Nygaard - One of the best experts on this subject based on the ideXlab platform.
-
Zuclopenthixol, Melperone and haloperidol/levomepromazine in the elderly. Meta-analysis of two double-blind trials at 15 nursing homes in Norway
Current Medical Research and Opinion, 1992Co-Authors: H A Nygaard, E Fuglum, K ElgenAbstract:SummaryA meta-analysis was carried out of the data from two double-blind. multi-centre studies with identical methodology which compared the effectiveness of treatment of elderly patients with zuclopenthixol and with other antipsychotic drugs. In one study, patients were treated for 4 weeks with either zuclopenthixol or Melperone; in the other, with either zuclopenthixol or a combination of haloperidol and levomepromazine. The meta-analysis evaluated the results of 96 patients, 49 in the zuclopenthixol group and 47 in the comparison group. Doses, which were adjusted to individual patient's needs, were low as shown by the percentages of defined daily doses for each of the study drugs. The results indicated that all three treatment alternatives were effective in the treatment of elderly patients with symptoms of agitation and hostility/aggressiveness. There was a trend, however, for zuclopenthixol to have a more rapid onset of effect. Zuclopenthixol also has the advantage for both patients and nursing stuff...
-
Zuclopenthixol, Melperone and haloperidol/levomepromazine in E. Fuglum,* M.D., the elderly. Meta-analysis of two double-blind trials at 15 nursing
1992Co-Authors: H A Nygaard, K Elgen, H Lundbeck, S CopenhagenAbstract:Summary A meta-analysis was carried out of the data ,from two double-blind. multi-centre studies with identical methodology which compared the effectiveness of treatment of elderly patients with zuclopenthixol and with other antipsychotic drugs. In one study, patients were treated ,for 4 weeks with either zuclopenthixol or Melperone; in the other; with either zuclopenthixol or a combination of haloperidol and levomepromazine. The meta-analysis evaluated the results of Yh patients, 49 in the zuclopenthixol group and 47 in the comparison group. Doses, which were adjusted to individual patienth needs, were low as shown by the percentages of defined daily doses for each of the study drugs. The results indicated that all three treatment alternatives were effective in the treatment of elderly patients with symptoms of agitation and hostilitylaggressiveness. There was a trend, however; for zuclopenthixol to have a more rapid onset of’ effect. Zuclopenthixol also has the advantage for both patients and nursing stuff’ that dosage is once daily. Only few and mild side-effects were reported with the three drug regimens.
-
zuclopenthixol Melperone and haloperidol levomepromazine in the elderly meta analysis of two double blind trials at 15 nursing homes in norway
Current Medical Research and Opinion, 1992Co-Authors: H A Nygaard, E Fuglum, K ElgenAbstract:SummaryA meta-analysis was carried out of the data from two double-blind. multi-centre studies with identical methodology which compared the effectiveness of treatment of elderly patients with zuclopenthixol and with other antipsychotic drugs. In one study, patients were treated for 4 weeks with either zuclopenthixol or Melperone; in the other, with either zuclopenthixol or a combination of haloperidol and levomepromazine. The meta-analysis evaluated the results of 96 patients, 49 in the zuclopenthixol group and 47 in the comparison group. Doses, which were adjusted to individual patient's needs, were low as shown by the percentages of defined daily doses for each of the study drugs. The results indicated that all three treatment alternatives were effective in the treatment of elderly patients with symptoms of agitation and hostility/aggressiveness. There was a trend, however, for zuclopenthixol to have a more rapid onset of effect. Zuclopenthixol also has the advantage for both patients and nursing stuff...
-
zuclopenthixol Melperone and haloperidol levomepromazine in e fuglum m d the elderly meta analysis of two double blind trials at 15 nursing
1992Co-Authors: H A Nygaard, K Elgen, H Lundbeck, S CopenhagenAbstract:Summary A meta-analysis was carried out of the data ,from two double-blind. multi-centre studies with identical methodology which compared the effectiveness of treatment of elderly patients with zuclopenthixol and with other antipsychotic drugs. In one study, patients were treated ,for 4 weeks with either zuclopenthixol or Melperone; in the other; with either zuclopenthixol or a combination of haloperidol and levomepromazine. The meta-analysis evaluated the results of Yh patients, 49 in the zuclopenthixol group and 47 in the comparison group. Doses, which were adjusted to individual patienth needs, were low as shown by the percentages of defined daily doses for each of the study drugs. The results indicated that all three treatment alternatives were effective in the treatment of elderly patients with symptoms of agitation and hostilitylaggressiveness. There was a trend, however; for zuclopenthixol to have a more rapid onset of’ effect. Zuclopenthixol also has the advantage for both patients and nursing stuff’ that dosage is once daily. Only few and mild side-effects were reported with the three drug regimens.